Resources from the same session
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
Presenter: Leslie Randall
Session: ESMO Virtual Plenary revisited
Resources:
Slides
Webcast
VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
Presenter: Dongsheng Yue
Session: ESMO Virtual Plenary revisited
Resources:
Slides
Webcast
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
Presenter: Huiping Li
Session: ESMO Virtual Plenary revisited
Resources:
Slides
Webcast
Q&A and discussion with the investigators
Session: ESMO Virtual Plenary revisited
Resources:
Webcast